NASDAQ · DMAC
DiaMedica Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for DMAC: Nov 11, 2026
DiaMedica Therapeutics Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.2. The reported EPS for the same quarter last year was $-0.17.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Dec 2026 | $-0.22 | $-0.22 | $-0.22 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · MarketBeat · BNK Invest- Zacks · Aug 26, 9:55 AM EDTWall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 130% in DiaMedica Therapeutics (DMAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- The Motley Fool · Aug 17, 9:29 PM EDTDiaMedica (DMAC) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 13, 12:00 PM EDTAll You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to BuyDiaMedica Therapeutics (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- MarketBeat · Aug 11, 9:04 AM EDTDiaMedica Therapeutics Q2 Earnings Call HighlightsDiaMedica Therapeutics (NASDAQ:DMAC) said its second-quarter progress centered on advancing DM199 across early-onset fetal growth restriction (FGR), preeclampsia and acute ischemic stroke, while the company reported a cash runway it expects to extend through 2027. President and
- The Motley Fool · Jun 1, 4:17 PM EDTDiaMedica (DMAC) Q4 2025 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- The Motley Fool · May 8, 11:25 AM EDTDiaMedica (DMAC) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · May 7, 1:42 PM EDTDiaMedica Therapeutics Q1 Earnings Call HighlightsDiaMedica Therapeutics (NASDAQ:DMAC) executives outlined progress across the company’s DM199 clinical programs in preeclampsia and acute ischemic stroke during the company’s first-quarter 2026 earnings call, while also reviewing quarter-end liquidity and spending trends as develo
- BNK Invest · Apr 8, 4:37 PM EDTDiaMedica Therapeutics Enters Oversold Territory (DMAC)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- NASDAQ.com · Mar 30, 2:00 PM EDTAfter-Hours Earnings Report for March 30, 2026 : PRGS, PHR, DMAC, AIRJ, SPCE, HQI, SGMO, RNXT, INLX, FTHMThe following companies are expected to report earnings after hours on 03/30/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Progress Software Corporation (PRGS)is reporting for the quarter ending February 28, 2026. The computer software company's
- RTTNews · Dec 18, 11:27 PM ESTAfter-Hours Biotech Rally: Inspira, MediciNova, DiaMedica Therapeutics Among Gainers(RTTNews) – Several small-cap biotech and healthcare names posted notable gains in Thursday's after-hours trading session, with investors reacting to recent corporate updates and clinical milestones.
- RTTNews · Dec 9, 12:04 AM ESTAfter-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance(RTTNews) – Biotechnology stocks saw notable movement in after-hours trading on Monday, with several companies posting strong gains. Below is a structured look at the key movers and the developments driving their performance.
- Fintel · Dec 6, 5:51 AM ESTDiaMedica Therapeutics (DMAC) Price Target Increased by 25.68% to 15.81The average one-year price target for DiaMedica Therapeutics (NasdaqCM:DMAC) has been revised to $15.81 / share. This is an increase of 25.68% from the prior estimate of $12.58 dated November 14, 2025. The price target is an average of many targets provided by
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for DiaMedica Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.